FASLOMAX
Description
Fulvestrant is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.
Fulvestrant is a selective estrogen receptor degrader (SERD) and was first in class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell’s normal protein degradation processes to destroy it.
INDICATIONS
Monotherapy
FASLOMAX is indicated for the treatment of:
INDICATIONS
Monotherapy
FASLOMAX is indicated for the treatment of:
- hormone receptor (HR)-positive, humanepidermalgrowth factor receptor 2 HER2-negative advanced breast cancer postmenopausalwomen not previously treated with endocrine therapy, or
- HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
Combination Therapy with Palbociclib
FASLOMAX is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
Combination Therapy with Palbociclib
FASLOMAX is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
| Generic Name | Strength | Standard | Type | Packing | Pack Size |
| Fulvestrant | 250 mg | IP | PFS | Vial | 1 Vial |